Wall Street brokerages expect that LivaNova PLC (NASDAQ:LIVN) will announce earnings of $0.91 per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for LivaNova’s earnings. The highest EPS estimate is $0.93 and the lowest is $0.88. LivaNova posted earnings of $1.01 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 9.9%. The business is expected to announce its next earnings report before the market opens on Wednesday, August 1st.

On average, analysts expect that LivaNova will report full year earnings of $3.58 per share for the current financial year, with EPS estimates ranging from $3.57 to $3.60. For the next year, analysts forecast that the business will report earnings of $3.94 per share, with EPS estimates ranging from $3.89 to $4.00. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover LivaNova.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, May 2nd. The company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.03. The firm had revenue of $250.40 million for the quarter, compared to analyst estimates of $245.18 million. LivaNova had a negative net margin of 1.99% and a positive return on equity of 9.23%. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.67 EPS.

A number of equities research analysts have recently issued reports on the stock. BidaskClub raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Stifel Nicolaus upped their price objective on shares of LivaNova from $115.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $128.00 price objective on shares of LivaNova in a research note on Wednesday, July 18th. Zacks Investment Research raised shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Finally, ValuEngine raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $90.50.

Shares of LivaNova traded down $1.74, reaching $112.29, during trading on Friday, MarketBeat reports. The company had a trading volume of 607,259 shares, compared to its average volume of 419,219. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of 33.92, a PEG ratio of 3.29 and a beta of 0.80. LivaNova has a 12 month low of $59.91 and a 12 month high of $114.72. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.85 and a quick ratio of 1.51.

In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $84.66, for a total transaction of $84,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Francesco Bianchi sold 1,830 shares of the stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $83.81, for a total transaction of $153,372.30. The disclosure for this sale can be found here. Insiders sold a total of 27,072 shares of company stock valued at $2,581,413 in the last ninety days. 0.41% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Cambiar Investors LLC boosted its position in LivaNova by 9.9% during the 2nd quarter. Cambiar Investors LLC now owns 6,036 shares of the company’s stock valued at $603,000 after buying an additional 545 shares during the period. Bank of Montreal Can boosted its position in LivaNova by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 4,411 shares of the company’s stock valued at $441,000 after buying an additional 582 shares during the period. Russell Investments Group Ltd. boosted its position in LivaNova by 3.3% during the 1st quarter. Russell Investments Group Ltd. now owns 24,407 shares of the company’s stock valued at $2,159,000 after buying an additional 776 shares during the period. Bollard Group LLC boosted its position in LivaNova by 2.4% during the 1st quarter. Bollard Group LLC now owns 35,850 shares of the company’s stock valued at $3,173,000 after buying an additional 850 shares during the period. Finally, Amalgamated Bank boosted its position in LivaNova by 12.8% during the 2nd quarter. Amalgamated Bank now owns 7,717 shares of the company’s stock valued at $770,000 after buying an additional 876 shares during the period. 84.58% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Recommended Story: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.